Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027
Table of Contents
1. Executive Summary
2. Worldwide Number of Persons Vaccinated with Influenza Vaccines and Forecast (2013 – 2027)
3. Worldwide Influenza Vaccines Market Revenue and Forecast (2013 – 2027)
4. Worldwide Influenza Vaccines Market Share and Y–o–Y Growth (%)
4.1 Number of Persons Vaccinated with Influenza Vaccines Share,2013 – 2027(%)
4.2 Influenza Vaccines Market Share,2013 - 2027(%)
5. Worldwide Influenza Vaccines Market Drivers and Inhibitors
5.1 Market Drivers
5.2 Market Inhibitors
6. Worldwide Influenza Vaccines Market, By Geography (Volume and Value),2013 – 2027
6.1 United States
6.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.1.2 United States Influenza Vaccines Market Revenue (2013 – 2027)
6.2 Canada
6.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.2.2 Canada Influenza Vaccines Market Revenue (2013 – 2027)
6.3 Germany
6.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.3.2 Germany Influenza Vaccines Market Revenue (2013 – 2027)
6.4 France
6.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.4.2 France Influenza Vaccines Market Revenue (2013 – 2027)
6.5 Italy
6.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.5.2 Italy Influenza Vaccines Market Revenue (2013 – 2027)
6.6 Spain
6.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.6.2 Spain Influenza Vaccines Market Revenue (2013 – 2027)
6.7 United Kingdom
6.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.7.2 United Kingdom Influenza Vaccines Market Revenue (2013 – 2027)
6.8 Netherlands
6.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.8.2 Netherlands Influenza Vaccines Market Revenue (2013 – 2027)
6.9 Sweden
6.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.9.2 Sweden Influenza Vaccines Market Revenue (2013 – 2027)
6.10 Denmark
6.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.10.2 Denmark Influenza Vaccines Market Revenue (2013 – 2027)
6.11 Poland
6.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.11.2 Poland Influenza Vaccines Market Revenue (2013 – 2027)
6.12 Norway
6.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.12.2 Norway Influenza Vaccines Market Revenue (2013 – 2027)
6.13 Finland
6.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.13.2 Finland Influenza Vaccines Market Revenue (2013 – 2027)
6.14 Ireland
6.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.14.2 Ireland Influenza Vaccines Market Revenue (2013 – 2027)
6.15 Belgium
6.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.15.2 Belgium Influenza Vaccines Market Revenue (2013 – 2027)
6.16 Australia
6.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.16.2 Australia Influenza Vaccines Market Revenue (2013 – 2027)
6.17 New Zealand
6.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.17.2 New Zealand Influenza Vaccines Market Revenue (2013 – 2027)
6.18 Japan
6.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.18.2 Japan Influenza Vaccines Market Revenue (2013 – 2027)
6.19 Brazil
6.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.19.2 Brazil Influenza Vaccines Market Revenue (2013 – 2027)
6.20 China
6.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.20.2 China Influenza Vaccines Market Revenue (2013 – 2027)
6.21 India
6.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.21.2 India Influenza Vaccines Market Revenue (2013 – 2027)
6.22 Rest of the World (ROW)
6.22.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2013 – 2027)
6.22.2 ROW Influenza Vaccines Market Revenue (2013 – 2027)
7. Recent Development in the Worldwide Influenza Vaccines Market
8. Worldwide Influenza Vaccines Market – Regulatory System
8.1 United States
8.2 Europe
8.3 Japan
9. Major Deals in the Worldwide Influenza Vaccines Market
9.1 Merger and Acquisitions
9.2 Collaboration Deals
9.3 Licensing Agreement
9.4 Exclusive Agreement
9.5 Distribution Agreement
10. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
10.1 Year 2020
10.2 Year 2019
11. Key Companies Analysis
11.1 Sanofi Pasteur
11.1.1 Business Overview
11.1.2 Influenza Vaccines Portfolio
11.1.3 Influenza Vaccines Value Sales Analysis
11.1.4 Promising Influenza Vaccines in the Clinical Development
11.1.5 Recent Development
11.2 GlaxoSmithKline (GSK)
11.2.1 Business Overview
11.2.2 Influenza Vaccines Portfolio
11.2.3 Influenza Vaccines Sales Value Analysis
11.2.4 Recent Development
11.3 Seqirus (CSL Limited)
11.3.1 Business Overview
11.3.2 Influenza Vaccines Portfolios
11.3.3 Influenza Vaccines Sales Value Analysis
11.3.4 Promising Influenza Vaccines in the Clinical Development
11.3.5 Recent Development
11.4 AstraZeneca
11.4.1 Business Overview
11.4.2 Influenza Vaccines Portfolio
11.4.3 Influenza Vaccines Sales Value Analysis
11.4.4 Recent Development
11.5 Gamma Vaccines Pty Ltd
11.5.1 Business Overview
11.5.2 Influenza Vaccines Portfolio
11.5.3 Recent Development
11.6 Hualan Biological Engineering Inc
11.6.1 Business Overview
11.6.2 Influenza Vaccines Portfolio
11.6.3 Recent Development
11.7 Shanghai Institute of Biological Products Co., Ltd.
11.7.1 Business Overview
11.7.2 Influenza Vaccine Portfolio
11.8 Mylan
11.8.1 Business Overview
11.8.2 Influenza Vaccine Portfolio
11.9 BioDiem
11.9.1 Business Overview
11.9.2 Influenza Vaccine Portfolio
11.9.3 Recent Development
12. Emerging Players
12.1 Novavax
12.1.1 Business Overview
12.1.2 Promising Influenza Vaccines in the Clinical Development
12.1.3 Recent Development
12.2 BiondVax Pharmaceuticals Ltd.
12.2.1 Business Overview
12.2.2 Promising Influenza Vaccines in the Clinical Development
12.2.3 Recent Development
12.3 Medicago
12.3.1 Business Overview
12.3.2 Promising Influenza Vaccines in the Clinical Development
12.3.3 Recent Development
12.4 Moderna Inc
12.4.1 Business Overview
12.4.2 Promising Influenza Vaccines in the Clinical Development
12.4.3 Recent Development
12.5 Pneumagen
12.5.1 Business Overview
12.5.2 Promising Influenza Vaccines in the Clinical Development
12.5.3 Recent Development
12.6 Altimmune
12.6.1 Business Overview
12.6.2 Promising Influenza Vaccines in the Clinical Development
12.6.3 Recent Development
12.7 Daiichi Sankyo
12.7.1 Business Overview
12.7.2 Promising Influenza Vaccines in the Clinical Development
12.7.3 Recent Development
12.8 FluGen
12.8.1 Business Overview
12.8.2 Promising Influenza Vaccines in the Clinical Development
12.8.3 Recent Development
12.9 Imutex
12.9.1 Business Overview
12.9.2 Promising Vaccines in the Clinical Development
List of Tables
Table 4–1: Worldwide Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2013 – 2019
Table 4–2: Worldwide Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2020 – 2027
Table 4–3: Worldwide Influenza Vaccines Market Share (Percent),2013 – 2019
Table 4–4: Worldwide Influenza Vaccines Market Share Forecast (Percent),2020 – 2027
Table 8–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 9–1: Merger & Acquisitions in the Influenza Vaccines Market
Table 9–2: Collaboration Deal in the Influenza Vaccines Market
Table 9–3: Licensing Agreement in the Influenza Vaccines Market
Table 9–4: Exclusive Agreement in the Influenza Vaccines Market
Table 9–5: Distribution Agreement in the Influenza Vaccines Market
Table 11–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 11–2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 12–1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 12–2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 12–3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 12–4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 12–5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 12–6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 12–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 12–8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 12–9: Imutex Promising Influenza Vaccines in the Clinical Development
List of Figures
Figure 2–1: Worldwide Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 2–2: Worldwide Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 3–1: Worldwide Influenza Vaccines Market (Million US$),2013 – 2019
Figure 3–2: Worldwide Influenza Vaccines Market Forecast (Million US$),2020 – 2027
Figure 6–1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–3: United States Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–7: Canada Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–11: Germany Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–15: France Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–16: France Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–19: Italy Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–23: Spain Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019
Figure 6–26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027
Figure 6–27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–31: Netherlands Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–35: Sweden Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–39: Denmark Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–43: Poland Influenza Vaccines Revenue Market (Million US$),2013 – 2019
Figure 6–44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–47: Norway Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–51: Finland Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–55: Ireland Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–59: Belgium Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–63: Australia Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–67: New Zealand Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–71: Japan Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 6–73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–75: Brazil Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–79: China Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–80: China Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2019 – 2027
Figure 6–83: India Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–84: India Influenza Vaccines Market Revenue Forecast (Million US$),2019 – 2027
Figure 6–85: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand),2013 – 2019
Figure 6–86: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027
Figure 6–87: ROW Influenza Vaccines Market Revenue (Million US$),2013 – 2019
Figure 6–88: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2020 – 2027
Figure 12–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 12–3: GSK Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 12–3: Seqirus Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–4: Sequirus Influenza Vaccines Net Sales Value Forecast (Million US$),2020 – 2027
Figure 12–5: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2013 – 2019
Figure 12–6: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2019 – 2027
Global BCG Vaccine Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 96
According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period.
The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
Global Peptide Cancer Vaccine Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 115
According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period.
The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 101
Market Overview of Global Cancer Vaccine market:
According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years.
A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 12-Dec-2023 Price: US 3380 Onwards Pages: 102
Market Overview of Global Lung Cancer Vaccines market:
According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Lung Cancer Vaccines,A cancer vaccine for lung cance
This report covers a research time span from 2018 to 2028, and ......
Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 07-Dec-2023 Price: US 3380 Onwards Pages: 105
Market Overview of Global Cancer Vaccines market:
According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 16-Nov-2023 Price: US 3380 Onwards Pages: 110
Market Overview of Global Dendritic Cell Cancer Vaccine market:
According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
Global BCG Vaccine Market Research Report 2023, Forecast to 2028
Published: 14-Nov-2023 Price: US 2680 Onwards Pages: 135
BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
Published: 14-Nov-2023 Price: US 3280 Onwards Pages: 105
BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
Infectious Vaccine Collaboration and Licensing Deals 2016-2023
Published: 01-Nov-2023 Price: US 3995 Onwards Pages: 300
Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
